Aider is a “pair-programming” tool that can use various providers as the AI back end, including a locally running instance of ...

The key themes that defined the year behind us will also shape the one ahead. The most-read articles of 2025 tracked a return ...

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic ...

International exhibition explores immigrant artists creating beyond predefined narratives. ‘OFF SCRIPT’ explores what happens when artists are not assigned a role. When familiar systems disappear, ...

Each month, hosts Keith Shaw and Matt Egan are joined by a top-tier panel of editors from Foundry’s global team to discuss hot technology topics and give insights from IT buyers in markets around the ...

Working It is the FT's workplace, future of work and leadership brand, led by Isabel Berwick. Sign up for Isabel's weekly Working It newsletter (here) which offers a sideways glance at the week's big ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Gordon Scott has been an active investor and ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...

Subscribe to our weekly newsletter for the latest in industry news, expert insights, dedicated information security content and online events.